1. Home
  2. BTOG vs AZTR Comparison

BTOG vs AZTR Comparison

Compare BTOG & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTOG

Bit Origin Limited

HOLD

Current Price

$0.83

Market Cap

3.4M

Sector

Finance

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.13

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTOG
AZTR
Founded
2018
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.5M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
BTOG
AZTR
Price
$0.83
$0.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
606.8K
1.4M
Earning Date
06-26-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.10
52 Week High
$5.96
$1.40

Technical Indicators

Market Signals
Indicator
BTOG
AZTR
Relative Strength Index (RSI) 22.64 34.02
Support Level $0.15 $0.12
Resistance Level $2.24 $0.23
Average True Range (ATR) 0.09 0.01
MACD -0.00 0.00
Stochastic Oscillator 0.00 21.89

Price Performance

Historical Comparison
BTOG
AZTR

About BTOG Bit Origin Limited

Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: